TipRanks
Advertisement
Advertisement

ALLO Stock Latest News

Buy Rating Reaffirmed on ALLO-329 Autoimmune Opportunity; Price Target Maintained at $14
RatingsBuy Rating Reaffirmed on ALLO-329 Autoimmune Opportunity; Price Target Maintained at $14
19d ago
ALLO
Allogene Therapeutics management to meet with Piper Sandler
PremiumThe Fly
Allogene Therapeutics management to meet with Piper Sandler
2M ago
ALLO
Allogene Therapeutics Announces Retirement of Chief Financial Officer
PremiumCompany Announcements
Allogene Therapeutics Announces Retirement of Chief Financial Officer
2M ago
8K
ALLO
Allogene Therapeutics CFO Geoffrey Parker to retire
PremiumThe Fly
Allogene Therapeutics CFO Geoffrey Parker to retire
2M ago
ALLO
Allogene Therapeutics Signals Progress Amid Key Risks
PremiumCompany Announcements
Allogene Therapeutics Signals Progress Amid Key Risks
2M ago
ALLO
Allogene Therapeutics files $500M mixed securities shelf
PremiumThe FlyAllogene Therapeutics files $500M mixed securities shelf
2M ago
ALLO
Allogene Therapeutics reports Q2 EPS (13c), consensus (15c)
Premium
The Fly
Allogene Therapeutics reports Q2 EPS (13c), consensus (15c)
2M ago
ALLO
Tyler Van Buren Reiterates Buy on Allogene, Citing Strong ALPHA3 Trial Momentum and De-Risking Efficacy/Safety Data for Off-the-Shelf CAR-T Cema-cel
Premium
Ratings
Tyler Van Buren Reiterates Buy on Allogene, Citing Strong ALPHA3 Trial Momentum and De-Risking Efficacy/Safety Data for Off-the-Shelf CAR-T Cema-cel
2M ago
ALLO
Allogene Therapeutics (ALLO) Q2 Earnings Cheat Sheet
PremiumPre-Earnings
Allogene Therapeutics (ALLO) Q2 Earnings Cheat Sheet
2M ago
ALLO
Allogene gets RMAT, Fast Track designations for cemacabtagene ansegedleucel
PremiumThe Fly
Allogene gets RMAT, Fast Track designations for cemacabtagene ansegedleucel
3M ago
ALLO
Allogene publishes Phase 1 data in Journal of Clinical Oncology
PremiumThe Fly
Allogene publishes Phase 1 data in Journal of Clinical Oncology
3M ago
ALLO
Citizens biotech analyst holds an analyst/industry conference call
PremiumThe Fly
Citizens biotech analyst holds an analyst/industry conference call
4M ago
ALLO
CLLS
Citizens biotech analysts hold an analyst/industry conference call
PremiumThe FlyCitizens biotech analysts hold an analyst/industry conference call
4M ago
ALLO
CLLS
Allogene Launches ATM Offering to Bolster Capital Flexibility
Premium
Company Announcements
Allogene Launches ATM Offering to Bolster Capital Flexibility
4M ago
8K
ALLO
Allogene Therapeutics Names Zachary Roberts as New CEO
Premium
Company Announcements
Allogene Therapeutics Names Zachary Roberts as New CEO
5M ago
8K
ALLO
Allogene Therapeutics says Zachary Roberts to succeed David Chang as CEO
PremiumThe Fly
Allogene Therapeutics says Zachary Roberts to succeed David Chang as CEO
5M ago
ALLO
Allogene Earnings Call Highlights Early CAR-T Momentum
PremiumCompany Announcements
Allogene Earnings Call Highlights Early CAR-T Momentum
5M ago
ALLO
Allogene Therapeutics Balances Bold Data With Rising Spend
PremiumCompany Announcements
Allogene Therapeutics Balances Bold Data With Rising Spend
5M ago
ALLO
Allogene’s UNIVERSAL Trial Completion: What ALLO-715 Data Could Mean for Investors
PremiumCompany Announcements
Allogene’s UNIVERSAL Trial Completion: What ALLO-715 Data Could Mean for Investors
5M ago
ALLO
Allogene Therapeutics reports Q1 EPS (18c), consensus (18c)
PremiumThe FlyAllogene Therapeutics reports Q1 EPS (18c), consensus (18c)
5M ago
ALLO
Allogene Highlights ALPHA3 Data and Extended Cash Runway
Premium
Company Announcements
Allogene Highlights ALPHA3 Data and Extended Cash Runway
5M ago
8K
ALLO
Allogene Therapeutics increases 2026 operating cash expense guidance
Premium
The Fly
Allogene Therapeutics increases 2026 operating cash expense guidance
5M ago
ALLO

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >